Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing acetaminophen-codeine combination product; this is a regulatory action, not a clinical efficacy trial.
FDA approval of a generic ramelteon formulation; this is a regulatory action, not a clinical evidence trial, and does not report efficacy or safety data.